Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|January 16, 2020
Novavax Granted Fast Track Designation for NanoFlu in Older Adults
Author(s)Pharmaceutical Technology Editors
FDA has granted fast track designation for Novavax’s NanoFlu, a recombinant quadrivalent flu vaccine, for use by adults age 65 years and older.
Advertisement
On Jan. 15, 2020, Novavax, a late-stage biotechnology company developing next-generation vaccines, announced that FDA has granted fast track designation for its NanoFlu, a recombinant quadrivalent seasonal influenza vaccine candidate, adjuvanted with Matrix-M, a next-generation, patented saponin-based adjuvant, for use by adults 65 years of age and older.
The vaccine is in an ongoing Phase III clinical trial intended to evaluate its immunogenicity and safety compared to the quadrivalent formulation of Fluzone, a Sanofi influenza vaccine. The trial’s primary objectives are to demonstrate non-inferior immunogenicity as measured by hemagglutination inhibition titers of vaccine homologous influenza strains compared to Fluzone, and to describe its safety profile. Top-line clinical data from the trial is expected to be presented by the end of the first quarter of 2020 and could support a biologics license application as well as future licensure of NanoFlu using FDA’s accelerated approval pathway.
“[FDA’s] decision to grant [f]ast [t]rack [d]esignation for NanoFlu reflects the urgent unmet medical need for a more effective vaccine against influenza, particularly in the older adult population, which often experiences serious and sometimes life-threatening complications, of the disease,” said Stanley C. Erck, president and CEO of Novavax, in a company press release. “We believe that NanoFlu will offer an innovative improvement compared to traditional egg-based vaccines, which frequently result in mismatch and poor effectiveness. We look forward to working closely with [FDA] through the expedited review process, accelerating the access to this vaccine for the most vulnerable populations.”
Source:
Advertisement
Related to this article
The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
Advertisement
Advertisement